Following the results of the DESTINY-Breast04 trial, trastuzumab deruxtecan gained regulatory approval for the treatment of metastatic BC with low HER2 expression since it prolonged overall survival compared to physician’s choice chemotherapy [3]. This evidence concerns the gene ERBB2 and breast cancer.